Printer Friendly

Abbott Laboratories Honors Outstanding Scientists and Engineers For Scientific Excellence, Leadership and Innovation.

Abbott Laboratories announced today that 28 Abbott scientists were inducted as new or promoted members to the company's prestigious Volwiler Society for their scientific excellence and leadership. Abbott additionally recognized an outstanding researcher and research team for their scientific leadership and innovation.

Abbott named Jack Henkin, Ph.D. outstanding researcher in recognition of his innovative contributions to Abbott's cancer research programs. Henkin, who resides in Illinois and is a biochemist with a broad-based knowledge of anticancer therapy, was recognized for his clear and measurable understanding of the drug development process and the application of science and technology to the goals of pharmaceutical research. He has championed six molecules in two distinct therapeutic areas that Abbott is using in human clinical trials. In addition, his agents are being pursued for treatment of cancers in companion animals with unprecedented responses in animals with normally terminal disease. He is a research fellow in the Volwiler Society, and has more than 19 years of Abbott service.

Abbott's HUMIRA(R) Discovery, Development and Production team, an internal group within Abbott's Global Pharmaceutical Research and Development organization, was recognized as the Outstanding Research Team for scientific innovation and their contribution to the success of Abbott's new treatment for rheumatoid arthritis (RA). HUMIRA, which received approval from the U.S. Food and Drug Administration (FDA) on Dec. 31, 2002, is the first human monoclonal antibody approved by the FDA for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active RA. Each team member made a significant contribution to overcoming the challenges that drove HUMIRA's ultimate success. Members of the HUMIRA Discovery, Development and Production team are Hans-Jurgen Krause, Ph.D., Peter Moesta, Ph.D., Achim Moller, Ph.D., Jochen Salfeld, Ph.D., and Brian Turner, Ph.D.

Rheumatoid arthritis is an incurable autoimmune disease that causes pain, stiffness and swelling around the joints, and can lead to disability and premature death. With RA, the immune system attacks healthy tissue, particularly those that line and cushion joints. More than two million Americans, and five million people worldwide, live with this crippling disease.

In keeping with Abbott Laboratories' long history of philanthropy, in addition to individual recognition, outstanding research honorees each receive a monetary award for donation to any college or university of their choice.

"Excellence in scientific innovation is central to our business of bringing promising new products to patients in therapeutic areas of significant unmet medical need," said Jeff M. Leiden, M.D., Ph.D., president and chief operating officer, pharmaceutical products group, and chief scientific officer, Abbott Laboratories. "This year's honorees demonstrate a powerful combination of leadership, expertise and creativity."

Abbott Laboratories established the Volwiler Society in 1985 to recognize the company's most distinguished scientists and engineers. Named for the late Ernest H. Volwiler, Ph.D., a scientist and former Abbott president and chairman of the board, the society encourages professional growth and constant pursuit of innovation and scientific discovery. Dr. Volwiler is recognized in the National Inventors Hall of Fame by the United States Patent Office for his part in the discovery of sodium pentothal, one of the world's most widely used anesthetic agents. The new appointees bring total membership to 189.

A committee of Abbott's scientific leaders elects and promotes members of the society. Candidates are evaluated on their ingenuity, scientific excellence, consistent productivity and performance at Abbott. There are four levels of membership: associate research fellow, research fellow, senior research fellow and distinguished research fellow. A list of all new and promoted Volwiler Society members follows:
 Newly elected Volwiler Society members:

 Illinois Bruce J. Dille, Ph.D.
 Massachusetts Gerald R. Carson
 Ohio Chron-Si Lai, Ph.D.
 Ohio Alan S. Ryan, Ph.D.
 Germany Peter A. Noertersheuser, Ph.D.
 Illinois James M. Trevillyan, Ph.D.
 Illinois Yisheng Chen, Ph.D.
 Illinois Gang Liu, Ph.D.
 Massachusetts Tariq Ghayur, Ph.D.
 Illinois Eric A. Schmitt, Ph.D.
 Illinois Devalina Law, Ph.D.
 Illinois Martin King, Ph.D.
 Illinois Gin C. Hsieh, Ph.D.
 Illinois Philip J. Hajduk, Ph.D.
 Illinois Andrew M. Petros, Ph.D.
 Illinois Robert A. Carr, Ph.D.
 Illinois Sandeep Dutta, Ph.D.
 Massachusetts Zehra Kaymakcalan, Ph.D.

 Promoted Volwiler Society members:
 Illinois Jill E. Hochlowski, Ph.D.
 Illinois Stephen W. Fesik, Ph.D.
 Illinois M-Akhteruzzaman Molla, Ph.D.
 Illinois George J. Dawson, Ph.D.
 Illinois Arthur A. Hancock, Ph.D.
 Illinois Dale J. Kempf, Ph.D.
 Illinois Michael R. Michaelides, Ph.D.
 Illinois Richard A. Rode, Ph.D.
 Illinois Steven J. Wittenberger, Ph.D.
 Illinois Hing L. Sham, Ph.D.

 Important HUMIRA Safety Information

Cases of tuberculosis (TB), frequently disseminated or extra pulmonary at clinical presentation, have been observed in patients receiving HUMIRA. Serious infections and sepsis, including fatalities, have been reported with the use of TNF-blocking agents, including HUMIRA.

Many of these infections occurred in patients on concomitant immunosuppressive therapy that in addition to their underlying disease could predispose them to infections. Other invasive opportunistic fungal infections have also been observed in patients treated with TNF-blocking agents, including HUMIRA.

TNF-blocking agents, including HUMIRA, have been associated in rare cases with exacerbation of demyelinating disease. The most frequent adverse events seen in the placebo-controlled clinical trials (HUMIRA vs. placebo) were injection site reactions (20 percent vs. 14 percent), upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo. As with any treatment program, the benefits and risks of HUMIRA should be carefully considered before initiating therapy.

About Abbott Laboratories

Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs more than 70,000 people and markets its products in more than 130 countries. In 2002, the company's sales were $17.7 billion.

Abbott's news releases and other information are available on the company's Web site at .

CONTACT: Jennifer Smoter of Abbott Laboratories, +1-847-935-8865

Web site:

Company News On-Call:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Oct 29, 2003
Previous Article:Datec Group Delivers Solutions for Air Pacific.
Next Article:Boeing Reports Third Quarter Results; Updates Outlook; -- Results reflect continued strong performance of defense and commercial airplane businesses...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters